Product
GS-0189
1 clinical trial
1 indication
Indication
Non-Hodgkin LymphomaClinical trial
A Phase 1 Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Patients With Relapsed/Refractory Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2022-03-31